Arati Rao

Executive Director Clinical Research, Kite-Gilead. Former Associate Professor of Medicine-Duke Cell Therapy. Tweets are personal

[Arati Rao @dukeleuk]

@DrTomFrieden This is so “pro-life!!”

[Arati Rao @dukeleuk]

Season 13 of 2020 needs to be discontinued after 6 episodes. Enough is enough!

[Arati Rao @dukeleuk]

@realDonaldTrump And didn’t @tedcruz and @marcorubio call you dangerous and deranged in 2015 and here they are kissing 🍑. Stop tweeting and help the country

[Arati Rao @dukeleuk]

Thank you!

[Rachel Hu @RachelHuMD]

This is great news for patients with R/R MCL!! Congrats to @dukeleuk and her team. Thankful for your hard work and to have you as a mentor!

[Arati Rao @dukeleuk]

Led at Hackensack by the amazing @AndreGoyMD 🙏🏼

[Dr. Andre Goy @AndreGoyMD]

Great News: The FDA has approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory mantle cell #lymphoma.

[Arati Rao @dukeleuk]

@drkomanduri It was a beast getting the right USAN, so any trade name at all was welcome. Someone said it sounds like Daenerys’ dragon and I hope it’s just as fierce!

[Arati Rao @dukeleuk]

Led at #DFCI by the magnificient Dr. Caron Jacobson!!

[Dana-Farber News @DanaFarberNews]

We are very excited to offer Tecartus as the first #CARTcell therapy for patients with relapsed mantle cell #lymphoma. Tecartus, approved today by the @US_FDA, is a significant advance for patients who relapse or don’t respond to prior therapies: https://t.co/Be1yOWyN40

[Dana-Farber News @DanaFarberNews]

We are very excited to offer Tecartus as the first #CARTcell therapy for patients with relapsed mantle cell #lymphoma. Tecartus, approved today by the @US_FDA, is a significant advance for patients who relapse or don’t respond to prior therapies: https://t.co/Be1yOWyN40

[Arati Rao @dukeleuk]

@MediHumdani Ha! I hope it’s just as fierce with respect to efficacy as those dragons!

[Arati Rao @dukeleuk]

This is epic! A broad label, accelerated approval that will help the many patients with relapsed refractory MCL! What an honor to have led this program with the most amazing team!

[Michael Wang, MD @michaelwangmd]

Congratulations to all patients and their families affected by mantle cell lymphoma! This is a milestone progress!
U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma | Gilead Sciences https://t.co/LCLwIdTupX

[Arati Rao @dukeleuk]

@JenaFriedman Would’ve been way worse if it was the other way around. I wouldn’t wish that even on COVID19.

[Arati Rao @dukeleuk]

@abeitin @drkomanduri @SylvesterCancer @DrSDNimer Thanks @abeitin for your support with this study.

[Arati Rao @dukeleuk]

@michaelwangmd Thank you Dr. Wang. Couldn’t have done this study without your expertise, help and utter passion for MCL! #youarethebest

[Arati Rao @dukeleuk]

@weisman_hannah Texted you and then realized I’m in Cali time. Thinking of you my friend. Praying hard for your father. He is going be well and home soon. Massive hugs Tanya.

[Arati Rao @dukeleuk]

@DavidZodda Here’s hoping he is better soon. A tip of the hat to all the doctors, nurses,lab personnel, respiratory therapists, inpatient pharmacists, unit coordinators, admissions and bed control staff, janitors and every single person working in the hospitals helping humankind right now.

[Michael Dickinson @mike_dickinson1]

To me- this is the blockbuster presentation at #ASH19 - #CART are highly effective in #mantle cell lymphoma #zuma2 #lymsm #ASH19. Really striking outcomes in a difficult to treat disease. https://t.co/cGGDcgsd6P

[Arati Rao @dukeleuk]

2 of 3 patients with BTKi failure MCL have a Complete remission with KTEX19. Thank you @michaelwangmd 🙏🏼 and all the investigators.

[Mark Roschewski @RoschewskiMD]

⁦@michaelwangmd⁩ presents data of ZUMA-2. 2 out of 3 patients with BTK-resistant MCL achieved CR. #ASH19

[Jayr Schmidt Filho @jayrsf_]

Great results shown by @michaelwangmd of the phase 2 ZUMA-2 trial for patients with R/R Mantle Cell Lymphoma treated with KTE-X19 CD19 CAR-T cell. Heavily pre treated population, specially after BTKi. Great overall response rate and durable responses. #ASH19

[Arati Rao @dukeleuk]

Thank you @AndreGoyMD for your support with the Z2 study.

[Dr. Andre Goy @AndreGoyMD]

ZUMA2 data on CART cells in R/R MCL suggests a new paradigm for B-cell Lymphoma. Greater than 90% response, 67% CR. Highly durable. Grateful to be part of this team and have a new option for our patients @JTCancerCenter @hackensackUMC.org #ASH19 @ASH_hematology

[Arati Rao @dukeleuk]

Grateful for the patients who enrolled in the Zuma2 study and for the physicians and research nurses who helped let this study enrolled.

[Graham Collins @graham74GC]

Wang
Zuma-2 KTE-X19 MCL
• high risk, enrichment for high Ki67, blastoid / pleomorphic
• all prior BTKi with most refractory to this line
• ORR 93% CRR 67%
• median PFS NR, 12.3mo median FU
• expected CRS and neurotox

This is impressive data in v high risk gp #ASH19 #lymsm